hSHIP induces S-phase arrest and growth inhibition in cervical cancer HeLa cells

Journal of Genetics and Genomics

Volumn 37, Issue 4, 2010, Pages 249-255

  He, Kangxia ^a   He, Jie ^a   Wang, Shengyu ^a   Yan, Jianghua ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

cell cycle; cell growth; HeLa cells; PI3K Akt; SH2 containing inositol 5 phosphatase (SHIP)

Indexed keywords

GREEN FLUORESCENT PROTEIN; LIPOFECTAMINE; MESSENGER RNA; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; GROWTH INHIBITION; HELA CELL; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UTERINE CERVIX CANCER;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL PROLIFERATION; FEMALE; GROWTH INHIBITORS; HELA CELLS; HUMANS; MICE; PHOSPHORIC MONOESTER HYDROLASES; S PHASE; UTERINE CERVICAL NEOPLASMS;

MUS MUSCULUS;

EID: 77951577545     PISSN: 16738527     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1673-8527(09)60043-6     Document Type: Article

References (32)

1. Lioubin M.N., Algate P.A., Tsai S., Carlberg K., Aebersold A., and Rohrschneider L.R. p150Ship, a signal transduction molecule with inositol polyphosphate-5-phosphatase activity. Genes Dev. 10 (1996) 1084-1095
2. Tu Z., Ninos J.M., Ma Z., Wang J.W., Lemos M.P., Desponts C., Ghansah T., Howson J.M., and Kerr W.G. Embryonic and hematopoietic stem cells express a novel SH2-containing inositol 5′-phosphatase isoform that partners with the Grb2 adapter protein. Blood 98 (2001) 2028-2038
3. Aman M.J., Lamkin T.D., Okada H., Kurosaki T., and Ravichandran K.S. The inositol phosphatase SHIP inhibits Akt/PKB activation in B cells. J. Biol. Chem. 273 (1998) 33922-33928
4. Hunter M.G., and Avalos B.R. Phosphatidylinositol 3′-kinase and SH2-containing inositol phosphatase (SHIP) are recruited by distinct positive and negative growth-regulatory domains in the granulocyte colony-stimulating factor receptor. J. Immunol. 160 (1998) 4979-4987
5. Kim C.H., Hangoc G., Cooper S., Helgason C.D., Yew S., Humphries R.K., Krystal G., and Broxmeyer H.E. Altered responsiveness to chemokines due to targeted disruption of SHIP. J. Clin. Invest. 104 (1999) 1751-1759
6. Liu Q., Sasaki T., Kozieradzki I., Wakeham A., Itie A., Dumont D.J., and Penninger J.M. SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival. Genes Dev. 13 (1999) 786-791
7. Damen J.E., Liu L., Rosten P., Humphries R.K., Jefferson A.B., Majerus P.W., and Krystal G. The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase. Proc. Natl. Acad. Sci. USA 93 (1996) 1689-1693
8. Zhang X., and Majerus P.W. Phosphatidylinositol signalling reactions. Semin. Cell Dev. Biol. 9 (1998) 153-160
9. Liu L., Damen J.E., Ware M., Hughes M., and Krystal G. SHIP, a new player in cytokine-induced signalling. Leukemia 11 (1997) 181-184
10. Boer A.K., Drayer A.L., and Vellenga E. Effects of overexpression of the SH2-containing inositol phosphatase SHIP on proliferation and apoptosis of erythroid AS-E2 cells. Leukemia 15 (2001) 1750-1757
11. Malbec O., Schmitt C., Bruhns P., Krystal G., Fridman W.H., and Daeron M. Src homology 2 domain-containing inositol 5-phosphatase 1 mediates cell cycle arrest by FcgammaRIIB. J. Biol. Chem. 276 (2001) 30381-30391
12. Phee H., Jacob A., and Coggeshall K.M. Enzymatic activity of the Src homology 2 domain-containing inositol phosphatase is regulated by a plasma membrane location. J. Biol. Chem. 275 (2000) 19090-19097
13. Helgason C.D., Damen J.E., Rosten P., Grewal R., Sorensen P., Chappel S.M., Borowski A., Jirik F., Krystal G., and Humphries R.K. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. 12 (1998) 1610-1620
14. Daley G.Q., Van Etten R.A., and Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247 (1990) 824-830
15. Elefanty A.G., Hariharan I.K., and Cory S. bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J. 9 (1990) 1069-1078
16. Heisterkamp N., Jenster G., ten Hoeve J., Zovich D., Pattengale P.K., and Groffen J. Acute leukaemia in bcr/abl transgenic mice. Nature 344 (1990) 251-253
17. Kelliher M.A., McLaughlin J., Witte O.N., and Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc. Natl. Acad. Sci. USA 87 (1990) 6649-6653
18. Coffer P.J., and Woodgett J.R. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families. Eur. J. Biochem. 201 (1991) 475-481
19. Hidalgo M., and Rowinsky E.K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19 (2000) 6680-6686
20. Osaki M., Oshimura M., and Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9 (2004) 667-676
21. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., Willson J.K., Markowitz S., Kinzler K.W., Vogelstein B., and Velculescu V.E. High frequency of mutations of the PIK3CA gene in human cancers. Science 304 (2004) 554
22. Shukla S., Maclennan G.T., Marengo S.R., Resnick M.I., and Gupta S. Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model. Prostate 64 (2005) 224-239
23. Zhang X.Y., Zhang H.Y., Zhang P.N., Lu X., and Sun H. Elevated phosphatidylinositol 3-kinase activation and its clinicopathological significance in cervical cancer. Eur. J. Obstet. Gynecol. Reprod. Biol. 139 (2008) 237-244
24. Levine D.A., Bogomolniy F., Yee C.J., Lash A., Barakat R.R., Borgen P.I., and Boyd J. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin. Cancer Res. 11 (2005) 2875-2878
25. Knobbe C.B., Trampe-Kieslich A., and Reifenberger G. Genetic alteration and expression of the phosphoinositol-3-kinase/Akt pathway genes PIK3CA and PIKE in human glioblastomas. Neuropathol. Appl. Neurobiol. 31 (2005) 486-490
26. Oda K., Stokoe D., Taketani Y., and McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 65 (2005) 10669-10673
27. Wang J., Kuropatwinski K., Hauser J., Rossi M.R., Zhou Y., Conway A., Kan J.L., Gibson N.W., Willson J.K., Cowell J.K., and Brattain M.G. Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis. Mol. Cancer Ther. 6 (2007) 1143-1150
28. Mancini A., Koch A., Wilms R., and Tamura T. The SH2-containing inositol 5-phosphatase (SHIP)-1 is implicated in the control of cell-cell junction and induces dissociation and dispersion of MDCK cells. Oncogene 21 (2002) 1477-1484
29. Xing W., and Hamaguchi M. Effects of SHIP-1 on MMP2 secretion and invasion of SR3Y1 cells. J. Genet. Genomics 34 (2007) 285-293
30. Kim S., Kang J., Hu W., Evers B.M., and Chung D.H. Geldanamycin decreases Raf-1 and Akt levels and induces apoptosis in neuroblastomas. Int. J. Cancer 103 (2003) 352-359
31. Altomare D.A., and Testa J.R. Perturbations of the AKT signaling pathway in human cancer. Oncogene 24 (2005) 7455-7464
32. Pines J. Cyclins and cyclin-dependent kinases: theme and variations. Adv. Cancer Res. 66 (1995) 181-212